How are Cochlear shares impacted by Trump's tariffs?

Will the company escape from the tariffs? Let's find out.

| More on:
a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cochlear Ltd (ASX: COH) shares have been bouncing around on Thursday.

In morning trade, the hearing solutions company's shares were down as much as 4.5% to $256.43.

But this afternoon, they have started to recover and currently sit 0.5% lower for the day at $266.74.

What is going on with Cochlear shares?

The company's shares were caught up in a broad market selloff this morning after US President Donald Trump made his big announcement.

From Saturday, the United States will put a minimum 10% tariff on foreign imports, including those from Australia, as part of what Trump has dubbed his "liberation day" economic plan.

This has been bad news for a number of ASX shares, such as Ansell Ltd (ASX: ANN), Breville Group Ltd (ASX: BRG), Lovisa Holdings Ltd (ASX: LOV), and Cettire Ltd (ASX: CTT). They have all fallen heavily today amid concerns over the impact that the trade tariffs could have on their respective businesses.

But what about Cochlear? How will it be impacted?

Well, the short answer is we don't know yet. Until greater detail is provided, Cochlear advised that it is unsure what the impact will be. However, there is reason to hope that the impact will not be material. This may explain why Cochlear shares have recovered from their intraday lows this afternoon.

Cochlear response

This morning, Cochlear released an announcement, explaining that it was a complex situation. It said:

There are complexities in understanding the application of the new tariff. Cochlear has long been importing its products under a chapter of the Harmonized Tariff Schedule of the United States that provides for duty-free importation on a range of products into the US, including hearing implants. We are expecting further detail in the US Customs and Border Protection Notice of Implementation, which is expected to be published in the next week. An update will be provided to the market in due course.

Judging by the way that Cochlear's shares have recovered today, it seems that some investors believe that the company will escape from the wrath of Trump's tariffs. Though, that will not be known for sure until the company releases a follow up announcement next week or the week after.

For now, the team at Citi are likely to see recent weakness as a buying opportunity. A note from last month reveals that the broker has a buy rating and $300.00 price target on the company's shares.

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has positions in Cochlear and Lovisa. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and Lovisa. The Motley Fool Australia has recommended Ansell, Cochlear, and Lovisa. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Female scientist working in a laboratory.
Healthcare Shares

Why are shares in this biotech charging higher after a capital raise?

More detail has been made public about clinical trial plans.

Read more »

Doctor checking patient's spine x-ray image.
Share Market News

Are these 2 ASX healthcare shares a buying opportunity after yesterday's crash?

ASX healthcare shares have faced headwinds in recent months, but these two could be undervalued.

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

Will Telix shares drop below $10?

Telix shares are trading in the red again today.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 large-cap healthcare shares just re-rated by experts

What do market analysts think of these mega healthcare companies?

Read more »

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Healthcare Shares

Guess which ASX 200 healthcare share is crashing 22% on Tuesday on European blow

Bad news out of Europe is weighing heavily on this stock today.

Read more »

man with his hand on his chin wondering about the AIM share price
Healthcare Shares

Are CSL shares as a buy, hold, or sell ahead of its results?

Let's see what Bell Potter is saying about this biotech giant ahead of its results.

Read more »

A female scientist sits at a microscope in a Universal Biosensors laboratory smiling while her colleague checks beakers of COVID-19 samples in the background.
Healthcare Shares

This probiotics company has just struck a distribution deal, sending its shares sharply higher

Shares in Biome Australia have jumped after the company announced a distribution deal for its probiotic products in Canada.

Read more »

A medical researcher wearing a white coat sits at her desk in a laboratory conducting a test.
Healthcare Shares

Massive capital raise to progress drug trials announced

This raise will set the company up for years.

Read more »